For the Inventor, By the Inventor

Enter assignee name

Wuppertal, Germany

Antisense Pharma Gmbh

USPTO Granted Patents = 10

EPO Patents = 1

Forward Citations = 268

Loading Chart...

Loading Chart...

18 inventors (with patents filed for the assignee):

Karl-Hermann Schlingensiepen (6 out of 14 patents)

Frank Jaschinski (2 out of 12 patents)

Anneliese Schneider (2 out of 2 patents)

4. Mechthild Kunst (2 out of 2 patents)

5. Reimar Schlingensiepen (2 out of 8 patents)

6. Anja-Katrin Bosserhoff (1 out of 4 patents)

7. Andreas Mitsch (1 out of 1 patent)

8. Bernd Betzler (1 out of 1 patent)

9. Hubert Heinrichs (1 out of 1 patent)

10. Susanne Schmaus (1 out of 1 patent)

11. Tanja Rothammer-Hampl (1 out of 1 patent)

12. Reinhard Buettner (1 out of 1 patent)

13. Mara Szyrach (1 out of 1 patent)

14. Guenter Auerbach (1 out of 1 patent)

15. Piotr Jachimczak (1 out of 1 patent)

10 patents: Sort by Forward Citations

1. 8936910 - Method for selective oligonucleotide modification (2015-01-20),

2. 8822425 - Dosage of oligonucleotides suitable for the treatment of tumors (2014-09-02),

3. D709183 - Pump for pharmaceutical and cosmetic products (2014-07-15),

4. D697204 - Pump for pharmaceutical and cosmetics products (2014-01-07),

5. 8476246 - Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system (2013-07-02),

6. 8177775 - Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique (2012-05-15),

7. 8148493 - Method for inhibiting 'melanoma inhibitory activity' MIA (2012-04-03),

8. 8097597 - Use of low doses of oligonucleotides antisense to TGF-β genes in the treatment of brain tumors (2012-01-17),

9. 7963956 - Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique (2011-06-21),

10. 7910563 - Antisense oligonucleotide to inhibit melanoma inhibitory activity, MIA (2011-03-22),

Antisense Pharma GmbH is a biopharmaceutical company focused on the development of antisense-based drugs for the treatment of cancer. The company's lead product, trabedersen, is a novel antisense compound being developed for the treatment of malignant glioma. Antisense Pharma GmbH is committed to advancing research and development in the field of antisense technology to improve outcomes for cancer patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

10 Patents

#43 in Wuppertal

#3,712 in Germany

#54,268 in the World

Wuppertal, Germany

Antisense Pharma Gmbh

Forward Citations = 268

18 inventors:

Karl-Hermann Schlingensiepen (6 out of 14 patents)

Frank Jaschinski (2 out of 12 patents)

Anneliese Schneider (2 out of 2 patents)

4. Mechthild Kunst (2 out of 2 patents)

5. Reimar Schlingensiepen (2 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…